Kexing Biopharm’s GB18 project received clearance of IND application from NMPA and FDA

SHENZHEN, China, May 28, 2025 /PRNewswire/ — On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its independently developed innovative product, GB18. Moreover, GB18…